Trial Profile
A Phase 1, placebo and positive-controlled, dose-escalation study to determine the safety, pharmacodynamics and pharmacokinetics of a single intravenous injection ofHSK3486 in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cipepofol (Primary) ; Propofol
- Indications Anaesthesia; Sedation
- Focus Adverse reactions; First in man; Pharmacodynamics
- Acronyms HSK3486 SAD
- Sponsors Sichuan Haisco Pharmaceutical
- 15 Jan 2021 Results published in the Anesthesia and Analgesia
- 15 Dec 2014 Addition of a cohort in the dosing schedule and reduction of dose of two other cohorts from 0.648 mg/kg and 0.972 mg/kg to 0.540 mg/kg and 0.648 mg kg respectively.
- 15 Dec 2014 Planned number of patients changed from 42 to 48, as reported by Australian New Zealand Clinical Trials Registry record.